Registration No. 333-183955

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

 


 

Post-Effective Amendment No. 2

 

to

 

Form F-3

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Novartis AG

(Exact name of Registrant as specified in its charter)

 

Novartis Inc.

(Translation of Registrant’s name into English)

 

Switzerland

(State or other jurisdiction of incorporation or organization)

 

Not Applicable

(I.R.S. Employer Identification No.)

 

Lichtstrasse 35

4056 Basel, Switzerland

+41 61 324 1111

(Address and telephone number of Registrant’s principal executive offices)

 

Novartis Capital Corporation
(Exact name of Registrant as
specified in its charter)

 

Novartis Securities Investment Ltd.
(Exact name of Registrant
as specified in its charter)

 

 

 

Not Applicable
(Translation of Registrant’s name into English)

 

Not Applicable
(Translation of Registrant’s name into English)

 

 

 

Delaware
(State or other jurisdiction of
incorporation or organization)

 

Bermuda
(State or other jurisdiction of
incorporation or organization)

 

 

 

26-3086456
(I.R.S. Employer Identification No.)

 

Not Applicable
(I.R.S. Employer Identification No.)

 

 

 

230 Park Avenue, 21st Floor
New York, New York 10169
+ 1 212 307 1122
(Address and telephone number of
Registrant’s principal executive offices)

 

131 Front Street
Hamilton, HM12, Bermuda
+1 441 296 8025
(Address and telephone number of
Registrant’s principal executive offices)

 

Dr. Felix R. Ehrat
Dr. Christian Rehm
Novartis AG
Lichtstrasse 35
CH-4056 Basel
Switzerland
+41 61 324 1111

(Name, address and telephone number of agent for service)

 

Copies of all communications to:

 

Bernd Bohr
Mayer Brown International LLP
201 Bishopsgate
London EC2M 3AF
+44 20 3130 3640

 

Stuart K. Fleischmann
Shearman & Sterling LLP
599 Lexington Ave
New York, NY 10022
+1 212 848 7527

 

Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.

 

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  o

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. x

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

 

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  x

 

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  o

 

 

 



 

Explanatory Note

 

The purpose of this Post-Effective Amendment No. 2 to the registration statement is to file certain exhibits to the registration statement.

 

2



 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 9.   Exhibits

 

Exhibit
Number

 

Description

1.1

 

Form of Underwriting Agreement (1)

 

 

 

4.1

 

Indenture, dated February 10, 2009 among Novartis Capital Corporation, Novartis Securities Investment Ltd. and Novartis Finance S.A., as issuers, Novartis AG, as guarantor, and HSBC Bank USA, National Association, as trustee (2)

 

 

 

4.2

 

Form of Guaranteed Debt Security (3)

 

 

 

4.3

 

Form of Guaranteed Debt Security for 2.400% Notes due 2022 (4)

 

 

 

4.4

 

Form of Guaranteed Debt Security for 3.700% Notes due 2042 (5)

 

 

 

4.5

 

Officer’s Certificate of Novartis Capital Corporation (6)

 

 

 

4.6

 

Form of Guaranteed Debt Security for 3.400% Notes due 2024

 

 

 

4.7

 

Form of Guaranteed Debt Security for 4.400% Notes due 2044

 

 

 

4.8

 

Officer’s Certificate of Novartis Capital Corporation

 

 

 

5.1

 

Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG, Novartis Capital Corporation and Novartis Securities Investment Ltd. (7)

 

 

 

5.2

 

Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG (8)

 

 

 

5.3

 

Opinion of Appleby, special Bermuda counsel to Novartis Securities Investment Ltd. (9)

 

 

 

5.4

 

Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation (10)

 

 

 

5.5

 

Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG (11)

 

 

 

5.6

 

Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation

 

 

 

5.7

 

Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG

 

 

 

12.1

 

Computation of Ratio of Earnings to Fixed Charges (12)

 

 

 

12.2

 

Computation of Ratio of Earnings to Fixed Charges (13)

 

 

 

23.1

 

Consent of Mayer Brown International LLP (included in Exhibits 5.1, 5.4 and 5.6)

 

 

 

23.2

 

Consent of Bär & Karrer AG (included in Exhibits 5.2, 5.5 and 5.7)

 

 

 

23.3

 

Consent of Appleby (included in Exhibit 5.3)

 

 

 

23.4

 

Consent of PricewaterhouseCoopers AG (14)

 

 

 

24.1

 

Powers of Attorney (15)

 

 

 

25.1

 

Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of HSBC Bank USA, National Association (16)

 

3



 


 

(1)

 

Incorporated by reference to Exhibit 1.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(2)

 

Incorporated by reference to Exhibit 4.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(3)

 

Incorporated by reference to Exhibit 4.2 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(4)

 

Incorporated by reference to Exhibit 4.3 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(5)

 

Incorporated by reference to Exhibit 4.4 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(6)

 

Incorporated by reference to Exhibit 4.5 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(7)

 

Incorporated by reference to Exhibit 5.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(8)

 

Incorporated by reference to Exhibit 5.2 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(9)

 

Incorporated by reference to Exhibit 5.3 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(10)

 

Incorporated by reference to Exhibit 5.4 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(11)

 

Incorporated by reference to Exhibit 5.5 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(12)

 

Incorporated by reference to Exhibit 12.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(13)

 

Incorporated by reference to Exhibit 12.2 of the Report on Form 6-K furnished to the SEC on February 18, 2014 with a statement of computation of the ratio of earnings to fixed charges

 

 

 

 

 

(14)

 

Incorporated by reference to Exhibit 23.4 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(15)

 

Incorporated by reference to the signature pages of Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(16)

 

Incorporated by reference to Exhibit 25.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

4



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant, Novartis AG, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment No. 2 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, on the 21st day of February, 2014.

 

 

Novartis AG

 

 

 

 

 

By:

 

 

/s/ HARRY KIRSCH

 

Name:

Harry Kirsch

 

Title:

Authorized Signatory

 

 

 

By:

 

 

/s/ DR. FELIX R. EHRAT

 

Name:

Dr. Felix R. Ehrat

 

Title:

Authorized Signatory

 

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 to the registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

*

 

Chief Executive Officer (principal executive officer)

 

February 21, 2014

Joseph Jimenez

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ HARRY KIRSCH

 

Chief Financial Officer (principal financial and accounting

 

February 21, 2014

Harry Kirsch

 

officer)

 

 

 

 

 

 

 

 

 

Chairman of the Board of Directors

 

February 21, 2014

Dr. Joerg Reinhardt

 

 

 

 

 

 

 

 

 

*

 

Vice Chairman of the Board of Directors

 

February 21, 2014

Dr. Ulrich Lehner

 

 

 

 

 

 

 

 

 

*

 

Vice Chairman of the Board of Directors

 

February 21, 2014

Dr. Enrico Vanni

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. Dimitri Azar

 

 

 

 

 

 

 

 

 

 

 

Director

 

February 21, 2014

Dr. Verena A. Briner

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. William Brody

 

 

 

 

 

Post-Effective Amendment No.2 to Registration Statement

 

5



 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. Srikant Datar

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Ann Fudge

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. Pierre Landolt

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. Andreas von Planta

 

 

 

 

 

 

 

 

 

 

 

Director

 

February 21, 2014

Dr. Charles L. Sawyers

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. Ing. Wendelin Wiedeking

 

 

 

 

 

 

 

 

 

 

 

Director

 

February 21, 2014

William T. Winters

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Dr. Rolf M. Zinkernagel

 

 

 

 

 

 

 

 

 

*

 

Authorized U.S. Representative

 

February 21, 2014

Barry Rosenfeld

 

 

 

 

 

Post-Effective Amendment No.2 to Registration Statement

 

6



 

Pursuant to the requirements of the Securities Act of 1933, the registrant, Novartis Capital Corporation, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment No. 2 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, on the 21st day of February, 2014.

 

 

Novartis Capital Corporation

 

 

 

 

 

By:

 

 

*

 

Name:

Helen Boudreau

 

Title:

Director and President (principal executive officer and principal financial and accounting officer)

 

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 to the registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

/s/ FELIX SENN

 

Chairman of the Board of Directors

 

February 21, 2014

Felix Senn

 

 

 

 

 

 

 

 

 

*

 

Director and President (principal executive officer and principal

 

February 21, 2014

Helen Boudreau

 

financial and accounting officer)

 

 

 

Post-Effective Amendment No.2 to Registration Statement

 

7



 

Pursuant to the requirements of the Securities Act of 1933, the registrant, Novartis Securities Investment Ltd., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment No. 2 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, on the 21st day of February, 2014.

 

 

Novartis Securities Investment Ltd.

 

 

 

 

 

By:

 

 

*

 

Name:

Simon Zivi

 

Title:

Chairman of the Board of Directors (principal executive officer and principal financial and accounting officer)

 

 

 

By:

 

 

*

 

Name:

Michael L. Jones

 

Title:

Deputy Chairman of the Board of Directors and Secretary

 

 

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 to the registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

*

 

Chairman of the Board of Directors (principal executive officer

 

February 21, 2014

Simon Zivi

 

and principal financial and accounting officer)

 

 

 

 

 

 

 

*

 

Deputy Chairman of the Board of Directors and Secretary

 

February 21, 2014

Michael L. Jones

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Felix Eichhorn

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 21, 2014

Timothy Faries

 

 

 

 

 

 

 

 

 

 

 

Alternate Director

 

February 21, 2014

Alison Dyer-Fagundo

 

 

 

 

 

 

 

 

 

*

 

Alternate Director

 

February 21, 2014

Tonesan Amissah

 

 

 

 

 

 

 

 

 

*

 

Authorized U.S. Representative

 

February 21, 2014

Barry Rosenfeld

 

 

 

 

 

Post-Effective Amendment No.2 to Registration Statement

 

8



 


*By his signature below, each of the undersigned, pursuant to a duly authorized power of attorney filed with the Securities and Exchange Commission, have signed this Post-Effective Amendment No. 2 to the registration statement on behalf of the person indicated.

 

 

/s/ FELIX SENN

 

Felix Senn

 

 

 

 

 

/s/ DR. FELIX R. EHRAT

 

Dr. Felix R. Ehrat

 

 

Post-Effective Amendment No.2 to Registration Statement

 

9



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

1.1

 

Form of Underwriting Agreement (1)

 

 

 

4.1

 

Indenture, dated February 10, 2009 among Novartis Capital Corporation, Novartis Securities Investment Ltd. and Novartis Finance S.A., as issuers, Novartis AG, as guarantor, and HSBC Bank USA, National Association, as trustee (2)

 

 

 

4.2

 

Form of Guaranteed Debt Security (3)

 

 

 

4.3

 

Form of Guaranteed Debt Security for 2.400% Notes due 2022 (4)

 

 

 

4.4

 

Form of Guaranteed Debt Security for 3.700% Notes due 2042 (5)

 

 

 

4.5

 

Officer’s Certificate of Novartis Capital Corporation (6)

 

 

 

4.6

 

Form of Guaranteed Debt Security for 3.400% Notes due 2024

 

 

 

4.7

 

Form of Guaranteed Debt Security for 4.400% Notes due 2044

 

 

 

4.8

 

Officer’s Certificate of Novartis Capital Corporation

 

 

 

5.1

 

Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG, Novartis Capital Corporation and Novartis Securities Investment Ltd. (7)

 

 

 

5.2

 

Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG (8)

 

 

 

5.3

 

Opinion of Appleby, special Bermuda counsel to Novartis Securities Investment Ltd. (9)

 

 

 

5.4

 

Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation (10)

 

 

 

5.5

 

Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG (11)

 

 

 

5.6

 

Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation

 

 

 

5.7

 

Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG

 

 

 

12.1

 

Computation of Ratio of Earnings to Fixed Charges (12)

 

 

 

12.2

 

Computation of Ratio of Earnings to Fixed Charges (13)

 

 

 

23.1

 

Consent of Mayer Brown International LLP (included in Exhibits 5.1, 5.4 and 5.6)

 

 

 

23.2

 

Consent of Bär & Karrer AG (included in Exhibits 5.2, 5.5 and 5.7)

 

 

 

23.3

 

Consent of Appleby (included in Exhibit 5.3)

 

 

 

23.4

 

Consent of PricewaterhouseCoopers AG (14)

 

 

 

24.1

 

Powers of Attorney (15)

 

 

 

25.1

 

Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of HSBC Bank USA, National Association (16)

 

10



 


 

(1)

 

Incorporated by reference to Exhibit 1.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(2)

 

Incorporated by reference to Exhibit 4.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(3)

 

Incorporated by reference to Exhibit 4.2 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(4)

 

Incorporated by reference to Exhibit 4.3 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(5)

 

Incorporated by reference to Exhibit 4.4 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(6)

 

Incorporated by reference to Exhibit 4.5 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(7)

 

Incorporated by reference to Exhibit 5.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(8)

 

Incorporated by reference to Exhibit 5.2 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(9)

 

Incorporated by reference to Exhibit 5.3 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(10)

 

Incorporated by reference to Exhibit 5.4 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(11)

 

Incorporated by reference to Exhibit 5.5 to Post-Effective Amendment No. 1 to Form F-3 (file no. 333-183955) filed with the SEC on September 21, 2012

 

 

 

 

 

(12)

 

Incorporated by reference to Exhibit 12.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(13)

 

Incorporated by reference to Exhibit 12.2 of the Report on Form 6-K furnished to the SEC on February 18, 2014 with a statement of computation of the ratio of earnings to fixed charges

 

 

 

 

 

(14)

 

Incorporated by reference to Exhibit 23.4 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(15)

 

Incorporated by reference to the signature pages of Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

 

 

 

 

(16)

 

Incorporated by reference to Exhibit 25.1 to Form F-3 (file no. 333-183955) filed with the SEC on September 18, 2012

 

11